Skip to main content

Olaparib in metastatic pancreatic cancer, the POLO trial

By 2 Giugno 2019Maggio 18th, 2021No Comments

The randomized phase III POLO trial found that maintenance therapy with the poly (ADP-ribose) polymerase inhibitor olaparib significantly delayed the progression of metastatic pancreatic cancer in patients with germline BRCA gene mutations compared with placebo (median progression-free survival = 7.4 months vs 3.8 months, respectively). Olaparib is already approved in various ovarian and breast cancer settings, but Polo tested it specifically in germline BRCA-positive pancreatic cancer subjects who were still responding to first-line platinum chemo. We met Hedy L. Kindler, Professor of Medicine and Medical Director of Gastrointestinal Oncology at University of Chicago Medicine during ASCO 2019.